34 results
6-K
EX-99.2
CNTB
Connect Biopharma Holdings Ltd
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
and planned preclinical studies and clinical trials, continue our research and development activities, build our facilities, increase our production capacity … collaborations or other arrangements with third parties, neither of which may occur.
Operating Expenses
Research and Development Expenses
Research
6-K
CNTB
Connect Biopharma Holdings Ltd
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
Statements of Loss
For Six Months Ended June 30,
Notes
RMB’000
USD’000
Note 2
Research and development expenses
Administrative expenses
Other … in the interim condensed consolidated statements of loss:
Six Months Ended June 30,
RMB’000
Research and development expenses
Administrative expenses
7.Other
6-K
CNTB
Connect Biopharma Holdings Ltd
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
Consolidated Statements of Loss
For Six Months Ended June 30,
Notes
RMB’000
USD’000
Note 2
Research and development expenses
Administrative expenses
Other … statements of loss:
Six Months Ended June 30,
RMB’000
Research and development expenses
Administrative expenses
CONNECT BIOPHARMA HOLDINGS LIMITED
Notes
F-1/A
CNTB
Connect Biopharma Holdings Ltd
12 Mar 21
Registration statement (foreign) (amended)
5:02pm
and estimated offering expenses payable by us. We intend to use the net proceeds from this offering to fund the research and development of our … , including CBP-233, and to fund other current and future research and development activities and for working capital and other general corporate
DRS
CNTB
Connect Biopharma Holdings Ltd
17 Dec 20
Draft registration statement
12:00am
payable by us. We intend to use the net proceeds from this offering to fund the research and development of our product candidates, including CBP-201 … and future research and development activities and for working capital and other general corporate purposes, which may include capital projects. See “Use
6-K
EX-99.3
cu34 tud9
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
6-K
EX-99.1
h96dp2b
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
DRS/A
psjgikkrtnlqac5ht
26 Jan 21
Draft registration statement (amended)
12:00am
424B4
7quxa jqz14d07fa9
19 Mar 21
Prospectus supplement with pricing info
4:49pm
F-1
zs5g56toyeue z8
26 Feb 21
Registration statement (foreign)
4:56pm
F-1/A
f073 fck29smfo6j
18 Mar 21
Registration statement (foreign) (amended)
6:15am
6-K
EX-99.1
hacth47j3 fc7q
11 Apr 23
Connect Biopharma Reports Full Year 2022 Financial Results
5:00pm
20-F
6j22lg0wod zqcp2b
31 Mar 22
Annual report (foreign)
4:33pm
6-K
EX-99.1
1c0ahmbjcg 6cm9s
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
6-K
EX-99.1
a4xs8 ab9nh8
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
6-K
EX-99.1
eyszm9f
31 Mar 22
Connect Biopharma Reports Full Year 2021 Financial Results
5:15pm
6-K
92mmheol8q5lc
1 Mar 22
Current report (foreign)
4:16pm
6-K
EX-99.1
u4fbwz16is249ol3jl
16 Apr 24
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
4:20pm